CDMO / CMOFounded 2000
WuXi AppTec Co., Ltd.
Shanghai, Shanghai, China
A large Chinese contract research, development, and manufacturing organization (CRDMO) spanning small-molecule drug discovery and synthesis, biologics testing, and pharmaceutical/medical device manufacturing for thousands of global biopharma customers; its biologics manufacturing arm was spun off separately as WuXi Biologics in 2017.
- Segment
- CDMO / CMO
- Headquarters
- Shanghai, Shanghai, China
- Founded
- 2000
- Website
- www.wuxiapptec.com
Notable facts
- Founded December 1, 2000 in Shanghai by organic chemist Ge Li and co-founders.
- Went public on the NYSE in 2007, was taken private in 2015 for roughly $3.3 billion, then relisted on the Shanghai and Hong Kong exchanges in 2018 after spinning off its biologics unit (WuXi Biologics) to Hong Kong in 2017.
- Reports roughly 39,000 employees and about 6,000 customers across some 20 global sites as of 2025.
- Named in the U.S. BIOSECURE Act (signed into law December 2025) over alleged China military ties, which the company has denied; as of June 2026 the U.S. Department of Defense listed WuXi AppTec on its Chinese military company list.
Sourcing guides
Sources. This profile is compiled from public reference data, WebSearch-verified against source 1. Data as of 2026-07-14. See methodology.
Sourcing a vendor in this segment today? We connect clinical operations, regulatory, and procurement teams with qualified cdmo / cmo vendors.
Request vendors